Peripheral alpha-synuclein levels in patients with genetic and non-genetic forms of Parkinson's disease. (April 2020)

• Record Type: Journal Article
• Authors: Emmanouilidou, Evangelia; Papagiannakis, Nikolaos; Kouloulia, Stella; Galaziou, Aikaterini; Antonellou, Roubina; Papadimitriou, Dimitra; Athanasiadou, Aglaia; Bozi, Maria; Koros, Christos; Maniati, Matina; Vekrellis, Kostas; Ioannou, Penelope C.; Stefanis, Leonidas
• Is Part Of: Parkinsonism & related disorders. Volume 73(2020)
• Page Start: 35
• Page End: 40
• Publication Date: 2020-04
• Subjects: Parkinson disease -- Alpha-synuclein -- Plasma -- Serum -- A53T; Parkinson's disease -- Periodicals; Movement disorders -- Periodicals; Movement Disorders -- Periodicals; Nerve Degeneration -- Periodicals; Nervous System Diseases -- Periodicals; Parkinson Disease -- Periodicals; Tremor -- Periodicals; Parkinson, Maladie de -- Périodiques; Parkinson's disease; 616.833
• DOI: 10.1016/j.parkreldis.2020.03.014
• Languages: English
• ISSNs: 1353-8020

Abstract

Abstract: Background: Variations of α-synuclein levels have been reported in serum and plasma in Parkinson's Disease (PD) Patients. Methods: Serum and plasma were obtained from PD patients without known mutations (GU-PD, n = 124)), carriers of the A53T/G209A point mutation in the α-synuclein gene ( SNCA ) (n = 29), and respective age-/sex-matched controls. Levels of total α-synuclein were assessed using an in-house ELISA assay. Results: A statistically significant increase of α-synuclein levels was found in serum, but not plasma, from GU-PD patients compared to healthy controls. A statistically significant decrease of α-synuclein levels was found in serum and plasma from symptomatic A53T mutation carriers compared to healthy controls. Plasma α-synuclein levels were modestly negatively correlated with UPDRS part III score and disease duration in A53T-PD patients. Conclusion: Increased α-synuclein levels in serum of GU-PD patients suggest a systemic deregulation of α-synuclein homeostasis in PD. The opposite results in A53T-PD highlight the complexity of α-synuclein homeostatic regulation in PD, and suggest the possibility of reduced expression of the mutant allele. Highlights: Serum α-synuclein levels are increased in PD patients. Serum and plasma α-synuclein levels are decreased in A53T mutation carriers. Plasma α-synuclein levels are negatively correlated with UPDRS part III score in A53T-PD patients. Plasma α-synuclein levels are negatively correlated with disease duration in A53T-PD patients.